NC State to Partner With ChromaGenix on Transformative Toolkit for Manufacturing Biological Therapies
ChromaGenix’s portfolio of technologies for purifying biological therapeutics originated in the College of Engineering and was initially commercialized by the NC State spinout company LigaTrap Technologies. The new partnership will focus on discovering and developing the next generation of affinity ligands for the purification of vital medicines.
NC State University will partner with ChromaGenix, a life science company that wants to transform the field of affinity purification technologies, on research to expand the company’s ligand discovery platform.
The five-year research project will seek to develop up to 10 novel ligands dedicated to the purification of emerging therapeutic modalities, including mRNA, plasmid DNA, exosomes, and viral vectors for gene and cell therapies.
- Categories:
